Shunsuke Kondo

Loop profile Researcher Name Resolver ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 26

Top Topics

Nitric Oxide Synthase

Squamous Cell Carcinoma

Top Venues

Cancer research communications

Cancer medicine

Expert opinion on pharmacotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Yasuyuki Kawamoto, Chigusa Morizane, Yoshito Komatsu, Shunsuke Kondo, Makoto Ueno, Satoshi Kobayashi, Masayuki Furukawa, Lingaku Lee, Taroh Satoh, Daisuke Sakai, Masafumi Ikeda, Hiroshi Imaoka, Arisa Miura, Yutaka Hatanaka, Isao Yokota, Yoshiaki Nakamura, Takayuki Yoshino
Phase II trial of niraparib for BRCA -mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B. Future oncology (London, England) (2024)
Takafumi Koyama, Kan Yonemori, Toshio Shimizu, Jun Sato, Shunsuke Kondo, Kazuki Sudo, Tatsuya Yoshida, Yuki Katsuya, Tatsuki Imaizumi, Masashi Enomoto, Ryoko Seki, Noboru Yamamoto
Phase 1 study of simlukafusp alfa (FAP-IL2v) with or without atezolizumab in Japanese patients with advanced solid tumors. Cancer research communications (2024)
Yasutoshi Kuboki, Takafumi Koyama, Nobuaki Matsubara, Yoichi Naito, Shunsuke Kondo, Kenichi Harano, Kan Yonemori, Kiyotaka Yoh, Yuan Gu, Tetsuya Mita, Xuejun Chen, Eiji Ueda, Noboru Yamamoto, Toshihiko Doi, Toshio Shimizu
PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study. Cancer medicine 13 (8) (2024)
Yasutoshi Kuboki, Takafumi Koyama, Nobuaki Matsubara, Yoichi Naito, Shunsuke Kondo, Kenichi Harano, Kan Yonemori, Kiyotaka Yoh, Yuan Gu, Tetsuya Mita, Xuejun Chen, Eiji Ueda, Noboru Yamamoto, Toshihiko Doi, Toshio Shimizu
PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study. Cancer medicine 13 (8) (2024)
Yasuyuki Kawamoto, Chigusa Morizane, Yoshito Komatsu, Shunsuke Kondo, Makoto Ueno, Satoshi Kobayashi, Masayuki Furukawa, Lingaku Lee, Taroh Satoh, Daisuke Sakai, Masafumi Ikeda, Hiroshi Imaoka, Arisa Miura, Yutaka Hatanaka, Isao Yokota, Yoshiaki Nakamura, Takayuki Yoshino
Phase II trial of niraparib for BRCA -mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B. Future oncology (London, England) (2024)
Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski, Gintautas Vainorius, Neil Gibson, Irene C Waizenegger, Daniel Gerlach, Martin Augsten, Fiona Spreitzer, Yukina Shirai, Masachika Ikegami, Sylvia Tilandyova, Dirk Scharn, Mark A Pearson, Johannes Popow, Anna C Obenauf, Noboru Yamamoto, Shunsuke Kondo, Frans L Opdam, Annemarie Bruining, Shinji Kohsaka, Norbert Kraut, John Victor Heymach, Flavio Solca, Ralph A Neumuller
Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers. Cancer discovery (2024)
Yasutoshi Kuboki, Takafumi Koyama, Nobuaki Matsubara, Yoichi Naito, Shunsuke Kondo, Kenichi Harano, Kan Yonemori, Kiyotaka Yoh, Yuan Gu, Tetsuya Mita, Xuejun Chen, Eiji Ueda, Noboru Yamamoto, Toshihiko Doi, Toshio Shimizu
PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study. Cancer medicine 13 (8) (2024)
Naoya Kato, Masatoshi Kudo, Kaoru Tsuchiya, Atsushi Hagihara, Kazushi Numata, Hiroshi Aikata, Yoshitaka Inaba, Shunsuke Kondo, Kenta Motomura, Naohiro Okano, Masafumi Ikeda, Manabu Morimoto, Shingo Kuroda, Akiko Kimura
Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase II study. Hepatology research : the official journal of the Japan Society of Hepatology (2023)
Kotaro Takeshita, Susumu Hijioka, Yoshikuni Nagashio, Yuta Maruki, Yuki Kawasaki, Kosuke Maehara, Yumi Murashima, Mao Okada, Go Ikeda, Natsumi Yamada, Tetsuro Takasaki, Daiki Agarie, Hidenobu Hara, Yuya Hagiwara, Kohei Okamoto, Daiki Yamashige, Akihiro Ohba, Shunsuke Kondo, Chigusa Morizane, Hideki Ueno, Yutaka Saito, Yuichiro Ohe, Takuji Okusaka
Diagnostic Ability of Endoscopic Ultrasound-Guided Tissue Acquisition Using 19-Gauge Fine-Needle Biopsy Needle for Abdominal Lesions. Diagnostics (Basel, Switzerland) 13 (3) (2023)
Kotaro Takeshita, Susumu Hijioka, Yoshikuni Nagashio, Yuta Maruki, Yuki Kawasaki, Kosuke Maehara, Yumi Murashima, Mao Okada, Go Ikeda, Natsumi Yamada, Tetsuro Takasaki, Daiki Agarie, Hidenobu Hara, Yuya Hagiwara, Kohei Okamoto, Daiki Yamashige, Akihiro Ohba, Shunsuke Kondo, Chigusa Morizane, Hideki Ueno, Yutaka Saito, Yuichiro Ohe, Takuji Okusaka
Diagnostic Ability of Endoscopic Ultrasound-Guided Tissue Acquisition Using 19-Gauge Fine-Needle Biopsy Needle for Abdominal Lesions. Diagnostics (Basel, Switzerland) 13 (3) (2023)
Tomoyuki Satake, Shunsuke Kondo, Noriko Tanabe, Takaaki Mizuno, Yuki Katsuya, Jun Sato, Takafumi Koyama, Tatsuya Yoshida, Makoto Hirata, Noboru Yamamoto
Pathogenic germline variants in BRCA1/2 and p53 identified by real-world comprehensive cancer genome profiling tests in Asian patients. Cancer research communications (2023)
Takeshi Takamoto, Yuta Maruki, Shunsuke Kondo
Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma. Expert opinion on pharmacotherapy (2023)
Takeshi Takamoto, Yuta Maruki, Shunsuke Kondo
Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma. Expert opinion on pharmacotherapy (2023)
Hanae Ida, Toshio Shimizu, Makoto Nishino, Yoshiaki Nakamura, Shu Yazaki, Yuki Katsuya, Jun Sato, Takafumi Koyama, Satoru Iwasa, Kazuki Sudo, Shunsuke Kondo, Kan Yonemori, Kohei Shitara, Satoshi Shiono, Daiko Matsuoka, Keisuke Yasuda, Yohei Otake, Takuya Suzuki, Takao Takase, Shuya Takashima, Kohei Yamaguchi, Taro Semba, Noboru Yamamoto
Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib. Cancer research communications 3 (7) (2023)
Izumi Komoto, Norihiro Kokudo, Taku Aoki, Chigusa Morizane, Tetsuhide Ito, Takuya Hashimoto, Wataru Kimura, Naoya Inoue, Kiyoshi Hasegawa, Shunsuke Kondo, Hideki Ueno, Hisato Igarashi, Takamasa Oono, Masatoshi Makuuchi, Takeshi Takamoto, Ichiro Hirai, Akiko Takeshita, Masayuki Imamura
Phase I/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors. Japanese journal of clinical oncology 52 (7) (2022)
Shunsuke Kondo, Satoru Iwasa, Takafumi Koyama, Tomoko Fujita, Ko Sugibayashi, Kosho Murayama, Noboru Yamamoto
Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study. International journal of clinical oncology 27 (12) (2022)
Yasutoshi Kuboki, Toshio Shimizu, Kan Yonemori, Takashi Kojima, Shunsuke Kondo, Shigehiro Koganemaru, Satoru Iwasa, Kenichi Harano, Takafumi Koyama, Vickie Lu, Xiaofei Zhou, Huifeng Niu, Tomoko Yanai, Ignacio Garcia-Ribas, Toshihiko Doi, Noboru Yamamoto
Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study. Cancer research communications 2 (11) (2022)
Yasutoshi Kuboki, Toshio Shimizu, Kan Yonemori, Takashi Kojima, Shunsuke Kondo, Shigehiro Koganemaru, Satoru Iwasa, Kenichi Harano, Takafumi Koyama, Vickie Lu, Xiaofei Zhou, Huifeng Niu, Tomoko Yanai, Ignacio Garcia-Ribas, Toshihiko Doi, Noboru Yamamoto
Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study. Cancer research communications 2 (11) (2022)
Satoru Iwasa, Takafumi Koyama, Makoto Nishino, Shunsuke Kondo, Kazuki Sudo, Kan Yonemori, Tatsuya Yoshida, Kenji Tamura, Toshio Shimizu, Yutaka Fujiwara, Shigehisa Kitano, Akihiko Shimomura, Jun Sato, Fumiharu Yokoyama, Hiroyuki Iida, Maki Kondo, Noboru Yamamoto
First-in-human study of ONO-4578, an antagonist of prostaglandin E 2 receptor 4, alone and with nivolumab in solid tumors. Cancer science (2022)
Chia-Chi Lin, Toshihiko Doi, Kei Muro, Ming-Mo Hou, Taito Esaki, Hiroki Hara, Hyun Cheol Chung, Christoph Helwig, Isabelle Dussault, Motonobu Osada, Shunsuke Kondo
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia. Targeted oncology 16 (4) (2021)
Toshihiko Doi, Noboru Yamamoto, Yoichi Naito, Yasutoshi Kuboki, Takafumi Koyama, Yongzhe Piao, Naoto Tsujimoto, Hiroya Asou, Koichi Inoue, Shunsuke Kondo
Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study. Cancer medicine 10 (19) (2021)
Shunsuke Kondo, Toshio Shimizu, Takafumi Koyama, Jun Sato, Satoru Iwasa, Kan Yonemori, Yutaka Fujiwara, Akihiko Shimomura, Shigehisa Kitano, Kenji Tamura, Noboru Yamamoto
First-in-human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors. Cancer science 112 (4) (2021)
Shunsuke Kondo, Masaomi Tajimi, Tomohiko Funai, Koichi Inoue, Hiroya Asou, Vinay Kumar Ranka, Volker Wacheck, Toshihiko Doi
Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer. Investigational new drugs 38 (6) (2020)
Takafumi Koyama, Toshio Shimizu, Satoru Iwasa, Yutaka Fujiwara, Shunsuke Kondo, Shigehisa Kitano, Kan Yonemori, Akihiko Shimomura, Sakura Iizumi, Tatsuya Sasaki, Junji Furuse, Noboru Yamamoto
First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. Cancer science 111 (2) (2020)
Kosuke Saito, Masafumi Ikeda, Yasushi Kojima, Hiroko Hosoi, Yoshiro Saito, Shunsuke Kondo
Lipid profiling of pre-treatment plasma reveals biomarker candidates associated with response rates and hand-foot skin reactions in sorafenib-treated patients. Cancer chemotherapy and pharmacology 82 (4) (2018)
Shunsuke Kondo, Hiroko Hosoi, Kota Itahashi, Jun Hashimoto
Quality evaluation of investigator-initiated trials using post-approval cancer drugs in Japan. Cancer science 108 (5) (2017)